obstructive-sleep-apnea
(4)
Mosanna Therapeutics
Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.
Wesper
Wesper is a New York-based sleep-health company that has built a wireless, wearable patch and cloud platform for clinical-grade, at-home sleep apnea testing. Founded in 2017 (originally as Tatch) by Dr. Amir Reuveny and Adi Mordechai, Wesper combines flexible printed electronics, machine learning, and a provider portal to replace the wires and single-night snapshots of traditional sleep labs with comfortable, repeatable, longitudinal testing. The FDA-cleared Wesper Lab lets patients test at home while giving physicians high-resolution data that correlates closely with in-lab polysomnography.
XII Medical
XII Medical is a Union City, California medical device company building a minimally invasive neuromodulation therapy for obstructive sleep apnea (OSA). Founded in 2017 and led by CEO Garrett Schwab, the company is developing an implantable platform designed to be smaller, more flexible and easier to implant than existing nerve-stimulation systems - an alternative for the estimated 425 million people worldwide with moderate-to-severe OSA who struggle with CPAP masks. Backed by Cleveland Clinic, Ajax Health, Omega Funds and Intuitive Ventures, XII Medical closed a $45M Series B in August 2024 to fund product and clinical development.
Siesta Medical, Inc.
Siesta Medical, Inc. is a privately held medical device company in Los Gatos, California that builds minimally invasive implants and instruments to treat obstructive sleep apnea (OSA). Its flagship AIRLIFT procedure - performed with the FDA-cleared Encore System and the Revolution Suture Passer - lets ear, nose and throat surgeons pull the hyoid bone and tongue base forward to keep the airway open during sleep. The knotless, fully adjustable approach takes roughly 30 minutes, works regardless of a patient's anatomy, BMI or apnea severity, and has been used in more than 2,000 patients.